Avalo Therapeutics (AVTX) Intangibles (2017 - 2021)

Avalo Therapeutics has reported Intangibles for 5 years, with the latest figure at $38000.0 in Q4 2021.

• For the quarter ending Q4 2021, Intangibles fell 97.6% year-over-year to $38000.0; the trailing twelve-month figure through Dec 2021 stood at $38000.0 (down 97.6% YoY), and the FY2021 full-year result was $38000.0, down 97.6% from the prior year.
• Intangibles for Q4 2021 stood at $38000.0, down from $304000.0 in the prior quarter.
• The five-year high for Intangibles was $33.1 million in Q1 2018, with the low at $38000.0 in Q4 2021.
• Historically, Intangibles has averaged $12.6 million across 5 years, with a median of $2.4 million in 2019.
• The largest YoY upside for Intangibles was 29.0% in 2021 against a maximum downside of 97.6% in 2021.
• Avalo Therapeutics' Intangibles stood at $17.7 million in 2017, then tumbled by 78.68% to $3.8 million in 2018, then sank by 35.57% to $2.4 million in 2019, then sank by 34.67% to $1.6 million in 2020, then sank by 97.6% to $38000.0 in 2021.
• The last three Intangibles figures came in at $38000.0 (Q4 2021), $304000.0 (Q3 2021), and $732000.0 (Q2 2021), per Business Quant data.